Actively Recruiting
Aberrant Expression of CD56 in Patients With Hematologic Malignancies
Led by Asmaa Hassan mohamed Abdel Mawjoud · Updated on 2026-03-18
38
Participants Needed
2
Research Sites
26 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are studying the expression pattern of CD56, a marker found on natural killer cells and other immune cells, in patients with hematologic malignancies. These blood cancers arise from bone marrow or lymphatic system cells and include diverse diseases such as leukemia, lymphoma, and multiple myeloma. While CD56 overexpression has been linked to certain conditions like acute myeloid leukemia, this study aims to explore its pattern across various hematologic cancers. The study involves detecting CD56 expression using a diagnostic test called flow cytometry. Participants include newly diagnosed patients with hematologic malignancies and control healthy individuals. This observational study will compare CD56 expression between these groups without administering any treatment. During the study, participants will undergo the CD56 detection test and provide samples for analysis. Researchers will measure how CD56 is expressed in different blood cancers over one year. The study also monitors participant health and gathers data to better understand the role of CD56 in these diseases. The total duration involves initial testing and follow-up evaluations as needed.
CONDITIONS
Brief Title
Aberrant Expression of CD56 in Patients With Hematologic Malignancies.
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with hematologic malignancies
- Newly diagnosed
You will not qualify if you...
- Patients with hematologic disorders other than hematologic malignancies
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 1 year
Participants undergo detection of CD56 by flow cytometry to evaluate its expression pattern in hematologic malignancies.
1 to 2 visits depending on cohort assignment
Duration - Up to 1 year
Participants are observed over time to monitor the expression pattern of CD56 and related outcomes.
Periodic visits during 1 year
Trial Site Locations
Total: 2 locations
1
Assiut University
Asyut, Egypt
Completed
2
Assiut university
Asyut, Egypt
Actively Recruiting
Research Team
A
asmaa H mohamed, R.DR
D
Dina A Mohareb, a.prof
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here